Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.
J Diabetes Sci Technol. 2024 Sep;18(5):1172-1178. doi: 10.1177/19322968231159360. Epub 2023 Mar 13.
For diabetes mellitus treatment plans, the consistency and quality of insulin drug products are crucial for patient well-being. Because biologic drugs, such as insulin, are complex heterogeneous products, the methods for drug product evaluation should be carefully validated for use. As such, these criteria are rigorously evaluated and monitored by national authorities. Consequently, reports that describe significantly lower insulin content than their label claims are a concern. This issue was raised by a past publication analyzing insulin drug products available in Canada, and, as a result, consumers and major patient organizations have requested clarification.
To address these concerns, this study independently analyzed insulin drug products purchased from local Canadian pharmacies-including human insulin, insulin analogs, and porcine insulin-by compendial and noncompendial reversed-phase high-performance liquid chromatography (RP-HPLC) methods.
We demonstrated the importance of using methods fit for purpose when assessing insulin quality. In a preliminary screen, the expected insulin peak was seen in all products except two insulin analogs-insulin detemir and insulin degludec. Further investigation showed that this was not caused by low insulin content but insufficient solvent conditions, which demonstrated the necessity for methods to be adequately validated for product-specific use. When drug products were appropriately assessed for content using the validated type-specific compendial RP-HPLC methods for insulin quantitation, values agreed with the label claim content.
Because insulin drug products are used daily by over a million Canadians, it is important that researchers and journals present data using methods fit for purpose and that readers evaluate such reports critically.
对于糖尿病治疗方案而言,胰岛素药物产品的一致性和质量对于患者的健康至关重要。由于胰岛素等生物药物是复杂的异质产品,因此应仔细验证药物产品评估方法的适用性。因此,这些标准由国家当局严格评估和监测。因此,有报道称胰岛素产品的实际含量明显低于标签声称的含量,这令人担忧。这一问题是由过去一篇分析加拿大市场上可用的胰岛素药物产品的出版物提出的,因此消费者和主要患者组织要求对此进行澄清。
为了解决这些问题,本研究通过使用非法定量的反相高效液相色谱法(RP-HPLC)和法定的 RP-HPLC 方法,对从当地加拿大药店购买的胰岛素药物产品(包括人胰岛素、胰岛素类似物和猪胰岛素)进行了独立分析。
我们证明了在评估胰岛素质量时使用适合目的的方法的重要性。在初步筛选中,除了两种胰岛素类似物(地特胰岛素和德谷胰岛素)外,所有产品都能看到预期的胰岛素峰。进一步的调查表明,这不是由于胰岛素含量低,而是由于溶剂条件不足造成的,这证明了方法需要针对特定产品进行充分验证的必要性。当使用针对胰岛素定量的经验证的特定类型法定 RP-HPLC 方法对药物产品进行适当评估时,结果与标签声称的含量相符。
由于每天有超过 100 万加拿大人使用胰岛素药物产品,因此研究人员和期刊使用适合目的的方法呈现数据,以及读者批判性地评估这些报告非常重要。